Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 21: Arrange the following drugs according to increasing volume of distribution: 1. Haloperidol 2. Gentamicin 3. Heparin 4. Chloroquine?

A. 3-2-4-1
B. 3-2-1-4 (Correct Answer)
C. 2-3-4-1
D. 2-1-3-4

Explanation: **Explanation:** The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration. It is determined by a drug's lipid solubility, ionization, and protein binding. 1. **Heparin ($V_d \approx 0.05$ L/kg):** Being a large, highly ionized molecule, it is confined almost entirely to the **plasma compartment**. It has the lowest $V_d$ among the options. 2. **Gentamicin ($V_d \approx 0.25$ L/kg):** As a polar/hydrophilic molecule (Aminoglycoside), it distributes into the **extracellular fluid (ECF)** but does not easily cross cell membranes. 3. **Haloperidol ($V_d \approx 15-20$ L/kg):** This is a lipophilic antipsychotic that crosses the blood-brain barrier and distributes into various tissues, resulting in a $V_d$ exceeding total body water. 4. **Chloroquine ($V_d \approx 13,000$ L/kg):** It is highly lipid-soluble and exhibits extensive **sequestration in tissues** (liver, spleen, lungs). It has one of the highest $V_d$ values in pharmacology. **Why Option B is correct:** The sequence **3 (Heparin) < 2 (Gentamicin) < 1 (Haloperidol) < 4 (Chloroquine)** correctly follows the progression from plasma-bound to ECF-bound to tissue-sequestered drugs. **Why other options are wrong:** * **Options A & C:** Incorrectly place Chloroquine before Haloperidol or Gentamicin before Heparin. * **Option D:** Incorrectly suggests Gentamicin has a lower $V_d$ than Heparin. **NEET-PG High-Yield Pearls:** * **Low $V_d$ (< 5L):** Drugs restricted to plasma (e.g., Heparin, Warfarin, Insulin). * **High $V_d$ (> 40L):** Drugs sequestered in tissues (e.g., Chloroquine, Digoxin, Amiodarone, TCAs). * **Clinical Significance:** Drugs with a high $V_d$ require a **Loading Dose** to achieve target plasma concentrations and are **not** effectively removed by hemodialysis during toxicity.

Question 22: Which of the following is a phase II drug metabolic reaction?

A. Oxidation
B. Cyclization
C. Methylation (Correct Answer)
D. Hydrolysis

Explanation: Drug metabolism (biotransformation) typically occurs in two phases to make lipophilic drugs more water-soluble for excretion. **Why Methylation is Correct:** **Phase II reactions** are **conjugation reactions** where an endogenous hydrophilic group (like glucuronic acid, sulfate, or a methyl group) is attached to the drug or its Phase I metabolite. **Methylation** is a classic Phase II reaction catalyzed by methyltransferase enzymes (e.g., COMT). Other Phase II reactions include Glucuronidation (most common), Acetylation, Sulfation, and Glutathione conjugation. **Why the Other Options are Incorrect:** * **A. Oxidation:** This is the most common **Phase I reaction**, primarily mediated by the Cytochrome P450 system. It involves the addition of oxygen or removal of hydrogen. * **B. Cyclization:** This is a **Phase I reaction** involving the formation of a ring structure from an open-chain compound. * **D. Hydrolysis:** This is a **Phase I reaction** where a bond is cleaved by the addition of water (common for esters and amides like Lidocaine or Aspirin). **NEET-PG High-Yield Pearls:** 1. **Phase I (Nonsynthetic):** Includes Oxidation, Reduction, Hydrolysis, Cyclization, and Decyclization. It introduces or unmasks a functional group (-OH, -NH2, -SH). 2. **Phase II (Synthetic):** Includes Glucuronidation, Acetylation, Methylation, Sulfation, and Glycine conjugation. 3. **Exception Rule:** Most drugs undergo Phase I followed by Phase II, but **Isoniazid (INH)** is a notable exception—it undergoes Phase II (Acetylation) followed by Phase I (Hydrolysis). 4. **Glucuronidation** is the only Phase II reaction that occurs in the Microsomes; all others occur in the Cytoplasm.

Question 23: The pharmacokinetic properties of a new drug are being studied in normal volunteers during phase I clinical trials. The volume of distribution and clearance determined in the first subject are 40 L and 2.0 L/hour, respectively. What is the approximate half-life of the drug in this subject?

A. 2 hours
B. 6 hours
C. 14 hours (Correct Answer)
D. 21 hours

Explanation: ### Explanation **1. Why Option C is Correct** The relationship between the half-life ($t_{1/2}$), volume of distribution ($V_d$), and clearance ($CL$) of a drug is defined by the following first-order kinetics formula [1]: $t_{1/2} = rac{0.693 \times V_d}{CL}$ **Calculation:** * Given $V_d = 40\text{ L}$ * Given $CL = 2.0\text{ L/hr}$ * $t_{1/2} = rac{0.693 \times 40}{2.0}$ * $t_{1/2} = 0.693 \times 20$ * $t_{1/2} = 13.86\text{ hours} \approx \mathbf{14\text{ hours}}$ The half-life is directly proportional to the volume of distribution (how widely the drug spreads in the body) and inversely proportional to the clearance (how fast the body removes the drug) [2]. **2. Why Other Options are Incorrect** * **Option A (2 hours):** This would occur if the clearance was much higher (approx. $14\text{ L/hr}$) or the $V_d$ much lower. * **Option B (6 hours):** This is a common distractor resulting from calculation errors or forgetting the $0.693$ constant. * **Option D (21 hours):** This value would be reached if the $V_d$ was $60\text{ L}$ or the clearance was reduced to $1.3\text{ L/hr}$. **3. Clinical Pearls for NEET-PG** * **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during continuous dosing. * **Elimination:** Similarly, it takes 4 to 5 half-lives for a drug to be effectively eliminated from the body (94–97% removal). * **$V_d$ and Dialysis:** Drugs with a very high $V_d$ (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be efficiently removed by hemodialysis. * **Clearance:** This is the most important parameter in determining the **Maintenance Dose**, whereas $V_d$ determines the **Loading Dose** [3].

Question 24: In drug metabolism, the hepatic cytochrome P-450 system is primarily responsible for which phase of reactions?

A. Phase I reactions (hydrolysis, oxidation, reduction etc.) (Correct Answer)
B. Phase II reactions (conjugation, synthesis etc.)
C. Both phase I and II reactions
D. Converting hydrophilic metabolites to lipophilic metabolites

Explanation: **Explanation:** **1. Why Option A is Correct:** Drug metabolism (biotransformation) occurs primarily in the liver to make drugs more polar for excretion. **Phase I reactions** involve non-synthetic processes like **Oxidation (most common), Reduction, and Hydrolysis**. These reactions introduce or unmask a functional group (e.g., -OH, -NH2, -SH). The **Cytochrome P-450 (CYP450)** system, located in the smooth endoplasmic reticulum (microsomes), is the primary enzymatic catalyst for these oxidative Phase I reactions. **2. Why Other Options are Incorrect:** * **Option B:** Phase II reactions are **conjugation reactions** (e.g., Glucuronidation, Acetylation, Sulfation). These are synthetic reactions that attach an endogenous molecule to the drug. They are mostly catalyzed by non-P450 enzymes (e.g., UDP-glucuronosyltransferase). * **Option C:** While both phases occur in the liver, the CYP450 system is specific to Phase I. * **Option D:** Metabolism aims to do the opposite—converting **lipophilic** drugs into **hydrophilic** (water-soluble) metabolites to facilitate renal or biliary excretion. **3. NEET-PG High-Yield Pearls:** * **CYP3A4:** The most abundant CYP isoform; responsible for metabolizing ~50% of all clinical drugs. * **Enzyme Inducers (Increase metabolism):** Phenytoin, Rifampin, Carbamazepine, Griseofulvin, Smoking (Mnemonic: **GPRS** Cell Phone). * **Enzyme Inhibitors (Decrease metabolism):** Erythromycin, Ketoconazole, Cimetidine, Valproate, Grapefruit juice (Mnemonic: **VITAMIN K**). * **Exception:** Most Phase II reactions occur in the cytosol, but **Glucuronidation** is microsomal (like Phase I). * **First-pass effect:** Drugs with high hepatic extraction (e.g., Propranolol, Nitroglycerin) have low oral bioavailability.

Question 25: Which of the following statements regarding Cytochrome P450 is FALSE?

A. Found only in bone marrow (Correct Answer)
B. CYP3A4 is the most common isoform
C. Participate in Phase 1 Xenobiotic reactions
D. They are present in Smooth Endoplasmic reticulum within cells

Explanation: **Explanation:** **Why Option A is the correct (False) statement:** Cytochrome P450 (CYP450) enzymes are **not** found only in the bone marrow. In fact, they are most abundantly expressed in the **liver** (the primary site of drug metabolism), followed by the enterocytes of the small intestine. While they exist in various extrahepatic tissues like the kidneys, lungs, and skin, their presence in the bone marrow is minimal and certainly not exclusive. **Analysis of other options:** * **Option B (CYP3A4 is the most common isoform):** This is true. CYP3A4 is the most abundant isoform in the liver and is responsible for metabolizing approximately 50% of all clinically used drugs. * **Option C (Participate in Phase 1 reactions):** This is true. CYP450 enzymes are the primary mediators of Phase 1 reactions, specifically **oxidation**, reduction, and hydrolysis, which aim to make drugs more polar. * **Option D (Present in Smooth Endoplasmic Reticulum):** This is true. These enzymes are membrane-bound hemoproteins located primarily in the **Smooth Endoplasmic Reticulum (SER)** of hepatocytes. When liver tissue is homogenized, these SER fragments form "microsomes," which is why they are often called microsomal enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Inducers (Increase metabolism):** Phenytoin, Rifampin, Carbamazepine, Griseofulvin, Smoking (Mnemonic: **GPRS Cell Phone**). * **Inhibitors (Decrease metabolism):** Erythromycin, Ketoconazole, Cimetidine, Valproate, Grapefruit juice (Mnemonic: **VITAMIN K**). * **Genetic Polymorphism:** Most commonly seen with **CYP2D6** (affects codeine and metoprolol metabolism). * **Non-Microsomal Enzymes:** These include Alcohol dehydrogenase, MAO, and Xanthine oxidase; unlike CYP450, these are **not** inducible.

Question 26: Which of the following is the most likely reason for pharmacokinetic tolerance?

A. Changes in absorption
B. Changes in distribution
C. Changes specific to that drug
D. Changes in metabolism (Correct Answer)

Explanation: **Explanation:** **Pharmacokinetic tolerance** (also known as metabolic or drug-disposition tolerance) occurs when the effective concentration of a drug at its site of action decreases over time despite repeated administration of the same dose. **Why "Changes in Metabolism" is correct:** The most common mechanism for pharmacokinetic tolerance is **enzyme induction**. Repeated exposure to certain drugs (e.g., Phenobarbitone, Carbamazepine, Alcohol) stimulates the synthesis of hepatic microsomal enzymes (Cytochrome P450). This leads to an increased rate of the drug's own metabolism (auto-induction), resulting in lower plasma levels and a diminished pharmacological effect. **Analysis of Incorrect Options:** * **A & B (Absorption and Distribution):** While changes in these parameters can affect drug levels, they are rarely the primary mechanism for *tolerance*. Tolerance implies a progressive adaptation; absorption and distribution usually remain relatively constant after the initial dosing phase. * **C (Changes specific to that drug):** This is a vague descriptor. While tolerance is drug-specific, the *mechanism* is defined by the physiological process involved (metabolism vs. pharmacodynamics/receptor down-regulation). **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacodynamic Tolerance:** Occurs due to changes in receptor sensitivity or number (e.g., down-regulation of $\beta$-receptors with chronic Albuterol use). * **Tachyphylaxis:** A form of "acute tolerance" that develops very rapidly (e.g., Ephedrine, Tyramine, Nitroglycerin). * **Barbiturates:** Classic examples of drugs that induce their own metabolism, necessitating higher doses to achieve the same sedative effect over time.

Question 27: A patient with normal renal function has received a daily maintenance dose of digoxin for 2 weeks. If the dosage is changed, in approximately how long would the new steady-state plasma digoxin concentration be achieved?

A. 2 days
B. 1 week (Correct Answer)
C. 2 weeks
D. 4 weeks

Explanation: The time required to reach a new steady-state concentration (Css) after a change in dosage is determined by the drug's **half-life ($t_{1/2}$)** [2]. It is a fundamental pharmacokinetic principle that steady state is achieved after **4 to 5 half-lives** of a drug [2]. Digoxin has a half-life of approximately **36 to 40 hours** (roughly 1.5 days) in a patient with normal renal function [1]. Therefore, approximately **1 week** is required to reach the new steady state. Digoxin has a **narrow therapeutic index** (0.5–2 ng/mL), plasma levels should only be measured after steady state is reached (i.e., after 1 week) to ensure accuracy [1].

Question 28: Exogenous adrenaline is metabolized by:

A. AChE
B. COMT (Correct Answer)
C. Decarboxylase
D. Acetyl transferase

Explanation: **Explanation:** The metabolism of catecholamines (Adrenaline, Noradrenaline, and Dopamine) involves two primary enzymes: **Catechol-O-methyltransferase (COMT)** and **Monoamine oxidase (MAO)**. **Why COMT is correct:** COMT is responsible for the O-methylation of catecholamines. When adrenaline is administered **exogenously**, it is primarily metabolized by COMT in the liver and kidneys. COMT acts on the catechol ring, converting adrenaline into metanephrine. In contrast, MAO is primarily located in the mitochondria of neuronal terminals and is more significant for the reuptake and degradation of endogenous (neuronal) catecholamines. **Why other options are incorrect:** * **AChE (Acetylcholinesterase):** This enzyme is specific for the rapid hydrolysis of **Acetylcholine** at cholinergic synapses. It has no role in catecholamine metabolism. * **Decarboxylase (L-amino acid decarboxylase):** This enzyme is involved in the **synthesis** (not metabolism) of catecholamines, specifically converting L-Dopa to Dopamine. * **Acetyl transferase:** This enzyme is involved in the metabolism of drugs like Isoniazid, Hydralazine, and Procainamide (via acetylation), but not adrenaline. **High-Yield Clinical Pearls for NEET-PG:** * **VMA (Vanillylmandelic acid):** The final common metabolic product of both adrenaline and noradrenaline. Elevated urinary VMA levels are a diagnostic marker for **Pheochromocytoma**. * **Metanephrines:** These are the intermediate metabolites (via COMT). Measuring plasma free metanephrines is currently considered the most sensitive screening test for Pheochromocytoma. * **COMT Inhibitors:** Drugs like **Entacapone** and **Tolcapone** are used in Parkinson’s disease to prevent the peripheral breakdown of Levodopa.

Question 29: What is the plasma half-life of aspirin?

A. Independent of dose
B. Longer for anti-inflammatory doses compared to analgesic doses (Correct Answer)
C. Shorter for anti-inflammatory doses compared to analgesic doses
D. Can be increased by alkalinizing the urine

Explanation: ### Explanation The plasma half-life of aspirin is unique because it exhibits **capacity-limited (saturable) metabolism**, shifting from first-order to zero-order kinetics as the dose increases. **1. Why Option B is Correct:** Aspirin is rapidly hydrolyzed to salicylic acid. At low **analgesic doses** (e.g., <600 mg), the metabolic pathways (conjugation with glycine and glucuronic acid) are unsaturated, following **first-order kinetics** with a half-life of about **3–5 hours**. However, at high **anti-inflammatory doses** (e.g., >3 g/day), these metabolic enzymes become saturated. The elimination shifts to **zero-order kinetics**, where a constant amount is cleared per unit of time regardless of concentration. This significantly prolongs the half-life to **15–30 hours**. **2. Why Other Options are Incorrect:** * **Option A:** Incorrect because aspirin follows non-linear kinetics; the half-life is highly dependent on the dose administered. * **Option C:** Incorrect because higher doses saturate clearance mechanisms, leading to a slower rate of elimination (longer half-life), not faster. * **Option D:** Alkalinizing the urine (using Sodium Bicarbonate) increases the ionization of salicylic acid (a weak acid). This traps the drug in the renal tubules and **increases renal excretion**, which actually **decreases** the plasma half-life. This is a standard treatment for salicylate poisoning. **High-Yield NEET-PG Pearls:** * **Zero-order kinetics mnemonic:** "**WATT**" – **W**arfarin (at high doses), **A**lcohol/Aspirin, **T**heophylline/Tolbutamide, **T**henytoin. * **Therapeutic Window:** Aspirin acts as an anti-platelet at low doses (<150 mg), analgesic/antipyretic at moderate doses (0.3–2 g), and anti-inflammatory at high doses (3–5 g). * **Salicylism:** Chronic toxicity characterized by tinnitus, dizziness, and hyperventilation.

Question 30: If the rate of elimination is directly proportional to plasma concentration, what is the order of kinetics?

A. Zero order
B. Pseudo-zero order
C. First order (Correct Answer)
D. Second order

Explanation: **Explanation:** **1. Why First-Order Kinetics is Correct:** In **First-Order Kinetics**, the rate of drug elimination is **directly proportional** to the plasma drug concentration ($C$). Mathematically, this is expressed as: $Rate = k \cdot C^1$. The underlying medical concept is that the elimination systems (enzymes/transporters) are not saturated. Therefore, a **constant fraction** (percentage) of the drug is eliminated per unit of time. Most drugs at therapeutic doses follow this model. As the concentration increases, the body clears more drug to maintain equilibrium. **2. Why the Other Options are Incorrect:** * **Zero-Order (A):** Here, the rate of elimination is **constant** and independent of plasma concentration ($Rate = k$). A constant amount (e.g., 10 mg/hour) is cleared because the elimination mechanisms are saturated. * **Pseudo-zero order (B):** This refers to drugs that follow first-order kinetics at low doses but shift to zero-order at higher/toxic doses as enzymes become saturated (e.g., Phenytoin, Aspirin, Alcohol). This is also known as **Michaelis-Menten** or Capacity-limited kinetics. * **Second order (D):** This involves the rate being proportional to the square of the concentration. It is rarely observed in clinical pharmacokinetics. **3. High-Yield Clinical Pearls for NEET-PG:** * **Half-life ($t_{1/2}$):** In First-order, $t_{1/2}$ is **constant** ($0.693/k$). In Zero-order, $t_{1/2}$ is variable (decreases as concentration decreases). * **Steady State:** It takes **4 to 5 half-lives** to reach steady-state plasma concentration ($C_{ss}$) for drugs following first-order kinetics. * **Zero-Order Mnemonic:** Remember **"WATT"** for drugs following Zero-order: **W**arfarin (at high doses), **A**lcohol/Aspirin, **T**heophylline/Tolbutamide, **T**henytoin (Phenytoin).

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free